TMCnet News
Research and Markets: US Autoimmune Diseases Market 2015 Report With Forecasts to 2019Research and Markets (http://www.researchandmarkets.com/research/zvlzr3/autoimmune) has announced the addition of the "Autoimmune Diseases Market in the US 2015-2019" report to their offering. US Autoimmune Diseases Market expected to Grow at a CAGR of 6.17% over the Period 2014-2019 Autoimmune diseases can affect the cardiovascular system, brain, nerves, musculoskeletal system, skin, lungs, kidneys, glands, or joints. They are caused by genetic, infectious, and environmental factors. According to NIH, there are more than 80 clinically different autoimmune diseases. Some of the common types of autoimmune diseases are ankylosing spondylitis, Crohn's disease, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, and psoriasis. Vendors are increasingly entering into alliances with universities, research institutes, and pharmaceutical companies for new drug development and to increase their market share. For instance, in 2015, Janssen-Cilag, a subsidiary of Janssen Pharmaceuticals, entered into an agreement with Monash University for the development of new medicines to treat rheumatoid arthritis and psoriasis. In 2014, MacroGenics and Takeda entered into an agreement for the development MGD010 for the treatment of systemic lupus erythematosus. In 2014, Kineta and Seattle Children's Research Institute announced the formation of an Alliance for Children's Therapeutics, a research collaboration for the development of new medicines in the treatment of autoimmune disorders such as multiple sclerosis and rheumatoid arthritis. Similarly, in 2013, Daiichi Sankyo and Amplimmune formed an alliance for the development of AMP-110, a biologic meant for the treatment of rheumatoid arthritis. According to the report, the high prevalence of autoimmune diseases is one of the major drivers in the market. An increasing number of people are being diagnosed with diseases such as Crohn's disease, multiple sclerosis, and rheumatoid arthritis. With the rise in the prevalence of autoimmune diseases, the demand for drugs is also increasing. The complex nature of autoimmune diseases and the high cost of treatment are major challenges to the growth of the market. Key Topics Covered
Companies Mentioned
For more information visit http://www.researchandmarkets.com/research/zvlzr3/autoimmune View source version on businesswire.com: http://www.businesswire.com/news/home/20150807005569/en/ |
